CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
Effective October 1, 2017, John Sperzel III, CEO and President of Chembio Diagnostics, Inc. ("Chembio") returned to work following a medical leave of absence. Sharon Klugewicz, who had served as acting Chief Executive Officer during Mr. Sperzel's medical leave of absence, will continue in her position as Chembio's President, Americas Region.
ITEM 8.01. OTHER EVENTS.
On September 28, 2017, the Company issued a press release entitled "ChembioAnnounces Return of President and CEO John Sperzel". A copy of the press release is included herewith as Exhibit99.1 and incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibits.
|
99.1 |
Press Release entitled "ChembioAnnounces Return of President and CEO John Sperzel" dated October 2, 2017. |
CHEMBIO DIAGNOSTICS, INC. ExhibitEX-99.1 2 ex99_1.htm EXHIBIT 99.1 FOR PRESS RELEASE Chembio Announces Return of President and CEO John Sperzel MEDFORD,…To view the full exhibit click here
About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)
Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
